艾力斯(688578.SH)2021年度預盈1698萬到2031萬元 同比扭虧為盈
格隆匯1月27日丨艾力斯(688578.SH)公佈,公司預計2021年年度實現歸屬於母公司所有者的淨利潤與上年同期(法定披露數據)相比,將實現扭虧為盈,實現歸屬於母公司所有者的淨利潤為1698萬元到2031萬元;歸屬於母公司所有者扣除非經常性損益後的淨利潤預計為-6334萬元到-6001萬元。
報吿期內,公司產品伏美替尼獲批上市,國內市場開始銷售並實現快速增長;公司與ArriVent簽署了海外授權協議,報吿期內確認了海外授權業務的相關收入。
報吿期內,公司利用IPO募集資金中按計劃在報吿期內未使用的部分募集資金以及流動資金滾動週轉過程中的閒置部分資金進行現金理財,理財收益較2020年有較大幅度增長。
2020年,公司產品伏美替尼尚未獲得上市批准,未產生銷售收入;公司其餘創新藥產品處於研發階段,未實現商業化。公司2020年度營業收入僅為56.09萬元,主要為合作開發蘭索拉唑腸溶膠囊分享的收益。因此,上年度收入基數較小。
報吿期內,公司在研項目推進導致研發費用相應增長;伏美替尼於2021年獲批,其商業化導致營銷費用有較大增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.